From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy.
Riccardo GiampieriPina ZiranuBruno DanieleAntonio ZizziDaris FerrariSara LonardiAlberto ZaniboniLuigi CavannaGerardo RosatiMariaelena CasagrandeNicoletta PellaLaura DemurtasMaria Giulia ZampinoPietro SozziValeria PuscedduDomenico GermanoEleonora LaiVittorina ZagonelCarla CodecàMichela LibertiniMarco PuzzoniRoberto LabiancaStefano CascinuMario ScartozziPublished in: Cancers (2020)
Our pre-planned, prospective analysis suggests that circulating FGF-2 levels' early increase could be used as a marker to identify patients who are more likely to gain benefit from FOLFIRI/bevacizumab first-line therapy.